Can-Fite BioPharma Ltd. (CANF)

Market Cap	13.23M
Revenue (ttm)	252,890
Net Income (ttm)	-3.55M
Shares Out	3.18M
EPS (ttm)	-1.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,214
Open	4.16
Previous Close	4.16
Day's Range	4.08 - 4.17
52-Week Range	3.78 - 12.90
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 23, 2023

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 8
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CANF

Financial Performance

In 2021, CANF's revenue was 853,000, an increase of 11.80% compared to the previous year's 763,000. Losses were -12.62 million, -12.66% less than in 2020.

Financial numbers in ILS